Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals
Inorganic Chemistry · 2023
DOI: 10.1021/acs.inorgchem.3c02164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inorganic Chemistry, 2023. Verfasst von Joshua J Woods und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States. Hauptthemen laut MEDLINE: Chelating Agents, Radiopharmaceuticals. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Basic Energy Sciences.
Abstract (Originalsprache)
Thorium-227 (227Th) is an α-emitting radionuclide that has shown preclinical and clinical promise for use in targeted α-therapy (TAT), a type of molecular radiopharmaceutical treatment that harnesses high energy α particles to eradicate cancerous lesions. Despite these initial successes, there still exists a need for bifunctional chelators that can stably bind thorium in vivo. Toward this goal, we have prepared two macrocyclic chelators bearing 1,2-hydroxypyridinone groups. Both chelators can be synthesized in less than six steps from readily available starting materials, which is an advantage over currently available platforms. The complex formation constants (log βmlh) of these ligands with Zr4+ and Th4+, measured by spectrophotometric titrations, are greater than 34 for both chelators, indicating the formation of exceedingly stable complexes. Radiolabeling studies were performed to show that these ligands can bind [227Th]Th4+ at concentrations as low as 10-6 M, and serum stability experiments demonstrate the high kinetic stability of the formed complexes under biological conditions. Identical experiments with zirconium-89 (89Zr), a positron-emitting radioisotope used for positron emission tomography (PET) imaging, demonstrate that these chelators can also effectively bind Zr4+ with high thermodynamic and kinetic stability. Collectively, the data reported herein highlight the suitability of these ligands for use in 89Zr/227Th paired radioimmunotheranostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.
- Nuclear Engineering, University of California Berkeley, Berkeley, California 94720, United States.
ORCID-Profile: Joshua J Woods, Stefan G Minasian, Rebecca J Abergel
Förderung
- Basic Energy Sciences
Zitieren
APA
Woods, J. J., Cosby, A. G., Wacker, J. N., Aguirre Quintana, L. M., Peterson, A., Minasian, S. G., & Abergel, R. J. (2023). Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals. Inorganic Chemistry. https://doi.org/10.1021/acs.inorgchem.3c02164
Vancouver
Woods JJ, Cosby AG, Wacker JN, Aguirre Quintana LM, Peterson A, Minasian SG, et al. Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals. Inorganic Chemistry. 2023. doi:10.1021/acs.inorgchem.3c02164
BibTeX
@article{Woods2023,
author = {Woods, Joshua J and Cosby, Alexia G and Wacker, Jennifer N and Aguirre Quintana, Luis M and Peterson, Appie and Minasian, Stefan G and Abergel, Rebecca J},
title = {Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals},
journal = {Inorganic Chemistry},
year = {2023},
doi = {10.1021/acs.inorgchem.3c02164}
}
EUVIMED